T6580
Triflusal
≥98% (HPLC), powder
别名:
Triflusal, α,α,α-trifluoro-2,4-cresotic acid acetate, 2-(Acetyloxy)-4-(trifluoromethyl)benzoic acid, Drisgen, acetyl-4-trifluoromethylsalicylic acid
SMILES string
FC(F)(F)c1cc(c(cc1)C(=O)O)OC(=O)C
InChI key
RMWVZGDJPAKBDE-UHFFFAOYSA-N
InChI
1S/C10H7F3O4/c1-5(14)17-8-4-6(10(11,12)13)2-3-7(8)9(15)16/h2-4H,1H3,(H,15,16)
assay
≥98% (HPLC)
form
powder
color
white to off-white
solubility
DMSO: >30 mg/mL
originator
Uriach
storage temp.
2-8°C
Quality Level
正在寻找类似产品? 访问 产品对比指南
Biochem/physiol Actions
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action.
Triflusal is an anti-inflammatory antithrombotic platelet aggregation inhibitor with a 3-fold mechanism of action. It is an irreversible inhibitor of COX-1 inhibiting thromboxane A2, preventing aggregation; it preserves vascular prostacyclin, thus promoting anti-aggregant effect. Triflusal blocks phosphodiesterase leading to an increase in cAMP levels promoting anti-aggregant effect due to inhibition of calcium mobilization.
Features and Benefits
This compound was developed by Uriach. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1 - STOT SE 3
target_organs
Respiratory system
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Carlos R Cámara-Lemarroy et al.
TheScientificWorldJournal, 11, 1886-1892 (2011-11-30)
Ischemia/reperfusion (I/R) is a condition that stimulates an intense inflammatory response. No ideal treatment exists. Triflusal is an antiplatelet salicylate derivative with anti-inflammatory effects. S-adenosylmethionine is a metabolic precursor for glutathione, an endogenous antioxidant. Dextromethorphan is a low-affinity N-methyl-D-aspartate receptor
Jung-Won Suh et al.
International heart journal, 50(6), 701-709 (2009-12-03)
Triflusal is a derivative of acetylsalicylic acid but it exhibits different pharmacological and pharmacokinetic properties. The object of this study was to evaluate the efficacy of additional use of triflusal in patients who underwent drug-eluting stent implantation. First, we prospectively
G Rodríguez et al.
Biomacromolecules, 11(10), 2740-2747 (2010-09-28)
The preparation, characterization, and analysis of physicochemical and biological properties of a new bioactive polymer system, based on a copolymer of an acrylic derivative of triflusal (a molecule with chemical structure related to aspirin with antiaggregating activity for platelets) is
Emilio García Quetglas et al.
Arzneimittel-Forschung, 58(6), 283-287 (2008-08-06)
Triflusal (CAS 322-79-2) is an antiplatelet agent related to salicylates used in several European and Latin American countries in the treatment of cardiovascular diseases. The aim of this paper was to evaluate the bioequivalence of triflusal derived from two preparations
Letter by Borja and Garcia-Rafanell regarding article, "Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association".
Javier Borja et al.
Stroke, 42(6), e388-e388 (2011-05-07)
商品
Bioactive small molecules for immune system signaling target identification/validation and antibiotics, antivirals, and antifungals offered.
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持